2 Followers USX:NEO - Neogenomics Inc. (USD 27.11) Neogenomics Inc.
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist
   


Yahoo Finance

USD 27.11    +0.890 (+3.39%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

9 Apr 2020


Overview

9 Apr 2020

Day Change: 0.890 (3.39%)

52 Wk Range: 18.52 - 34.965

Day's Range: 25.77 - 27.38

Last Volume: 881,889

Current Yield: 0%

Projected Yield: 0%

Open: USD 26.74

9 Apr 2020

Metric NEO S.Median
Beta 1.06 0.84
VaR 28.11 25.23
E.Shortfall 43.6 45.03
Liquidity 815.42K 95.2K

Fundamental

9 Apr 2020

PE: 350.862

Market Cap: 2.8B

Price Over Book: 5.536

Price Over Sales: 6.87

Return On Assets: 1.1%

Return On Equity: 1.6%

Price Over NAV: [Friends Only]

General

CEO: Douglas M. Van Oort

Headquarters: FORT MYERS

Employees: 1,500

Sector: Health Technology

Industry: Medical Specialties

Useful Links
Homepage

Description

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.